Eleven Biotherapeutics completes exclusive licensing deal for IL-6 antagonist antibody technology
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).
Click on this link for more information.
